Literature DB >> 25178500

Decade in review--acute coronary syndromes: Successes and future objectives in acute coronary syndrome.

Frans Van de Werf1.   

Abstract

The past decade has seen considerable advances in the treatment of acute coronary syndromes (ACS), particularly in the search for improved antithrombotic therapies. Despite these successes, however, renewed efforts are needed to improve long-term outcomes after ACS by reducing recurrent ischaemic events and lowering the risk of bleeding complications.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25178500     DOI： 10.1038/nrcardio.2014.129

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  10 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Early versus delayed invasive intervention in acute coronary syndromes.

Authors:  Shamir R Mehta; Christopher B Granger; William E Boden; Philippe Gabriel Steg; Jean-Pierre Bassand; David P Faxon; Rizwan Afzal; Susan Chrolavicius; Sanjit S Jolly; Petr Widimsky; Alvaro Avezum; Hans-Jurgen Rupprecht; Jun Zhu; Jacques Col; Madhu K Natarajan; Craig Horsman; Keith A A Fox; Salim Yusuf
Journal:  N Engl J Med       Date:  2009-05-21       Impact factor: 91.245

3.  Door-to-balloon time and mortality among patients undergoing primary PCI.

Authors:  Daniel S Menees; Eric D Peterson; Yongfei Wang; Jeptha P Curtis; John C Messenger; John S Rumsfeld; Hitinder S Gurm
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

4.  Vorapaxar in the secondary prevention of atherothrombotic events.

Authors:  David A Morrow; Eugene Braunwald; Marc P Bonaca; Sebastian F Ameriso; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; Stephen D Wiviott; John Strony; Sabina A Murphy
Journal:  N Engl J Med       Date:  2012-03-24       Impact factor: 91.245

5.  Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.

Authors:  Sanjit S Jolly; Salim Yusuf; John Cairns; Kari Niemelä; Denis Xavier; Petr Widimsky; Andrzej Budaj; Matti Niemelä; Vicent Valentin; Basil S Lewis; Alvaro Avezum; Philippe Gabriel Steg; Sunil V Rao; Peggy Gao; Rizwan Afzal; Campbell D Joyner; Susan Chrolavicius; Shamir R Mehta
Journal:  Lancet       Date:  2011-04-04       Impact factor: 79.321

6.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

7.  Bivalirudin during primary PCI in acute myocardial infarction.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Ajay J Kirtane; Helen Parise; Roxana Mehran
Journal:  N Engl J Med       Date:  2008-05-22       Impact factor: 91.245

8.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.

Authors:  Adeel Shahzad; Ian Kemp; Christine Mars; Keith Wilson; Claire Roome; Rob Cooper; Mohammed Andron; Clare Appleby; Mike Fisher; Aleem Khand; Babu Kunadian; Joseph D Mills; John L Morris; William L Morrison; Shahzad Munir; Nick D Palmer; Raphael A Perry; David R Ramsdale; Periaswamy Velavan; Rod H Stables
Journal:  Lancet       Date:  2014-07-04       Impact factor: 79.321

9.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting.

Authors:  Jean-Philippe Collet; Thomas Cuisset; Grégoire Rangé; Guillaume Cayla; Simon Elhadad; Christophe Pouillot; Patrick Henry; Pascal Motreff; Didier Carrié; Ziad Boueri; Loic Belle; Eric Van Belle; Hélène Rousseau; Pierre Aubry; Jacques Monségu; Pierre Sabouret; Stephen A O'Connor; Jérémie Abtan; Mathieu Kerneis; Christophe Saint-Etienne; Olivier Barthélémy; Farzin Beygui; Johanne Silvain; Eric Vicaut; Gilles Montalescot
Journal:  N Engl J Med       Date:  2012-11-04       Impact factor: 91.245

10.  Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.

Authors:  Paul W Armstrong; Anthony H Gershlick; Patrick Goldstein; Robert Wilcox; Thierry Danays; Yves Lambert; Vitaly Sulimov; Fernando Rosell Ortiz; Miodrag Ostojic; Robert C Welsh; Antonio C Carvalho; John Nanas; Hans-Richard Arntz; Sigrun Halvorsen; Kurt Huber; Stefan Grajek; Claudio Fresco; Erich Bluhmki; Anne Regelin; Katleen Vandenberghe; Kris Bogaerts; Frans Van de Werf
Journal:  N Engl J Med       Date:  2013-03-10       Impact factor: 176.079
  10 in total
  1 in total

1.  Efficacy and safety of quadruple therapy including tirofiban in the treatment of Chinese NSTE-ACS patients failing to receive timely percutaneous coronary intervention.

Authors:  Lan Li; Zhenrong Ge; Dengke Zhang; Jun Kuang; Xiang Ma; Shubin Jiang
Journal:  Drug Des Devel Ther       Date:  2017-11-21       Impact factor: 4.162
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.